BiotechTube

Ibrexafungerp

Phase 1Completed
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Vulvovaginal Candidiasis

Conditions

Vulvovaginal Candidiasis, Candida Infection, Vaginal Candidiasis

Trial Timeline

Jul 12, 2023 → Nov 1, 2023

NCT ID
NCT06954493

About Ibrexafungerp

Ibrexafungerp is a phase 1 stage product being developed by Scynexis for Vulvovaginal Candidiasis. The current trial status is completed. This product is registered under clinical trial identifier NCT06954493. Target conditions include Vulvovaginal Candidiasis, Candida Infection, Vaginal Candidiasis.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (4)

NCT IDPhaseStatus
NCT06954493Phase 1Completed
NCT05668429Phase 1Completed
NCT05399641Phase 3Completed
NCT03059992Phase 3Completed

Competing Products

10 competing products in Vulvovaginal Candidiasis

See all competitors
ProductCompanyStageHype Score
SHR8008 + FluconazoleJiangsu Hengrui MedicinePhase 3
77
SHR8008 capsule + Fluconazole capsuleJiangsu Hengrui MedicinePhase 3
77
Estradiol 10 MCG Vaginal Tablet [VAGIFEM] + Promestriene VaginalNovo NordiskPhase 3
76
FluconazolePfizerPhase 3
76
Clotrimazole vaginal tablet + FluconazoleBayerApproved
82
SCY-078 + FluconazoleScynexisPhase 2
44
IbrexafungerpScynexisPhase 3
69
Fluconazole Tablet + IBREXAFUNGERP + Placebo oral tabletScynexisPhase 3
69
Estradiol + PlaceboTherapeuticsMDPhase 3
69
Oral Encochleated Amphotericin B (CAMB) + Oral Encochleated Amphotericin B (CAMB)Matinas BiopharmaPhase 2
44

Other Products from Scynexis

IbrexafungerpPhase 3
69
SCY-078Phase 3
69
IbrexafungerpPhase 3
69
Fluconazole Tablet + IBREXAFUNGERP + Placebo oral tabletPhase 3
69
SCY-078 + Fluconazole + EchinocandinPhase 3
69